Clinical Trial Update: Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring neurocognitive function after switching from Efavirenz to Rilpivirine in people with HIV-1 infection and neurocognitive dysfuncti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Neurocognitive Dysfunction

Drugs mentioned

• EFAVIRENZ (efavirenz)
• rilpivirine (rilpivirine)

Snippet

Sponsor: Chiang Mai University | Conditions: HIV-1-infection, Neurocognitive Dysfunction | Phase 4 | Status: UNKNOWN